A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Conferences uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • Standard cytotoxic treatments for neuroendocrine tumours have been associated with limited activity and remarkable toxicity. A phase II study was designed to evaluate the efficacy, safety and pharmacodynamics of temsirolimus in patients with advanced neuroendocrine carcinoma (NEC). Thirty-seven patients with advanced progressive NEC received intravenous weekly doses of 25 mg of temsirolimus. Patients were evaluated for tumour response, time to progression (TTP), overall survival (OS) and adverse events (AE). Twenty-two archival specimens, as well as 13 paired tumour biopsies obtained pretreatment and after 2 weeks of temsirolimus were assessed for potential predictive and correlative markers. The intent-to-treat response rate was 5.6% (95% CI 0.6-18.7%), median TTP 6 months and 1-year OS rate 71.5%. The most frequent drug-related AE of all grades as percentage of patients were: fatigue (78%), hyperglycaemia (69%) and rash/desquamation (64%). Temsirolimus effectively inhibited the phosphorylation of S6 (P=0.02). Higher baseline levels of pmTOR (phosphorylated mammalian target of rapamycin) (P=0.01) predicted for a better response. Increases in pAKT (P=0.041) and decreases in pmTOR (P=0.048) after treatment were associated with an increased TTP. Temsirolimus appears to have little activity and does not warrant further single-agent evaluation in advanced NEC. Pharmacodynamic analysis revealed effective mTOR pathway downregulation.


  • Duran, I
  • Kortmansky, J
  • Singh, D
  • Hirte, H
  • Kocha, W
  • Goss, G
  • Le, L
  • Oza, A
  • Nicklee, T
  • Ho, J
  • Birle, D
  • Pond, Gregory
  • Arboine, D
  • Dancey, J
  • Aviel-Ronen, S
  • Tsao, M-S
  • Hedley, D
  • Siu, LL

publication date

  • November 2006

has subject area